1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Ocugen, Inc.
  6. News
  7. Summary
    OCGN   US67577C1053


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Ocugen, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01/21/2022 | 06:12pm EDT

MALVERN, Pa., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 787,268 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 217,681 shares of common stock to three newly hired team members. The stock options and RSUs were granted on January 10, 2022, and January 17, 2022, as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4). 687,872 of the stock options and 190,198 of the RSUs were issued on January 10, 2022, to a new member of the management team, whose appointment will be announced at a later date.

The stock options have a ten-year term and exercise prices of $4.32 and $4.25 per share, which were the closing prices of Ocugen’s common stock on January 10 and January 14, respectively. The stock options and RSUs vest in equal annual installments over a three-year period starting on the one-year anniversary of the grant date, subject to the applicable new employee’s continued service with Ocugen through the applicable vesting dates. The stock options and RSUs were granted outside of Ocugen’s 2019 Equity Incentive Plan.

About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug — “one to many,” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets. For more information, please visit www.ocugen.com. 

Cautionary Note on Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release. 

Ocugen Contact: 
Ken Inchausti
Head, Investor Relations & Communications

Primary Logo

Source: Ocugen

2022 GlobeNewswire, Inc., source Press Releases

All news about OCUGEN, INC.
05/13INSIDER SELL : Ocugen
05/09Chardan Trims Ocugen's Price Targe to $3.50 From $4, Maintains Neutral Rating
05/09Chardan Research Adjusts Ocugen's Price Target to $3.50 From $4, Maintains Neutral Rati..
05/06OCUGEN, INC. Management's Discussion and Analysis of Financial Condition and Results o..
05/06TRANSCRIPT : Ocugen, Inc., Q1 2022 Earnings Call, May 06, 2022
05/06Ocugen's Q1 Net Loss Widens
05/06OCUGEN, INC. : Results of Operations and Financial Condition, Other Events, Financial Stat..
05/06Ocugen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
05/06OCUGEN : Q1 Earnings Snapshot
05/06Ocugen Provides Business Update and First Quarter 2022 Financial Results
More news
Analyst Recommendations on OCUGEN, INC.
More recommendations
Financials (USD)
Sales 2022 14,5 M - -
Net income 2022 -62,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -7,47x
Yield 2022 -
Capitalization 483 M 483 M -
Capi. / Sales 2022 33,3x
Capi. / Sales 2023 4,04x
Nbr of Employees 56
Free-Float 98,4%
Duration : Period :
Ocugen, Inc. Technical Analysis Chart | OCGN | US67577C1053 | MarketScreener
Technical analysis trends OCUGEN, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 2,24 $
Average target price 7,38 $
Spread / Average Target 229%
EPS Revisions
Managers and Directors
Shankar Musunuri Chairman & Chief Executive Officer
Jessica Crespo CFO, Chief Accounting Officer & SVP-Finance
Arun Upadhyay Senior Vice President-Research & Development
Bruce D. Forrest Chief Medical Officer
Nirdosh Jagota SVP-Regulatory Affairs, Compliance & Safety
Sector and Competitors
1st jan.Capi. (M$)
OCUGEN, INC.-54.73%444
MODERNA, INC.-45.78%54 775
LONZA GROUP AG-29.81%40 137
IQVIA HOLDINGS INC.-30.08%37 337
SEAGEN INC.-7.50%26 323